Skip to main content
GutCited

Omega-3 Fatty Acids (EPA/DHA) pour Ulcerative Colitis (UC)

C Preuves Preuves limitées issues de petites études, mais certains signaux positifs existent.

Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

En conclusion

Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.

Key Study Findings

Review
Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.
Dose: None vs: None Outcome: None Effet: None None

Population: patients with ulcerative colitis

Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None vs: None Outcome: IBD microbiota modulation and immune regulation Effet: None None

Population: IBD patients (review of nutritional interventions)

Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None vs: None Outcome: Athletic performance and nutritional optimization Effet: None None

Population: Vegan athletes (narrative review)

Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None vs: None Outcome: Diet-genetics interaction in IBD Effet: None None

Population: IBD patients (editorial commentary)

Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None vs: None Outcome: Colitis severity Effet: None None

Population: Crohn's disease patients

Key Statistics

8

Études

1000

Participants

↔

Mixed

C

Note

Referenced Papers

Gastroenterology clinics of … 2018 67 citations
Annals of gastroenterology 2016 80 citations
European journal of … 2016 79 citations
Clinics in dermatology 2016 19 citations
World journal of … 2014 25 citations
Alimentary pharmacology & … 2013 128 citations
The British journal … 2012 145 citations
The Cochrane database … 2012 130 citations
JRSM short reports 2010 11 citations
The Cochrane database … 2007 118 citations
Journal of the … 2002 2016 citations
Drugs 1998 99 citations
Bailliere's clinical gastroenterology 1997 26 citations
The American journal … 1991 2278 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
1,000-2,000 mg combined EPA/DHA per day
ibdsupport:
2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)

Limite supérieure : 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Mixed --
None -- Neutral --
None -- Neutral --
95% -- Mixed --
95% -- Mixed 124

Moment optimal de prise : With meals containing fat for better absorption

Safety & Side Effects

Effets indésirables signalés

  • ⚠ Fishy aftertaste and burping
  • ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
  • ⚠ Potential increased bleeding time at very high doses (>3 g/day)
  • ⚠ May lower blood pressure slightly

Interactions connues

  • ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • ● Blood pressure medications (additive hypotensive effect)
  • ● Orlistat (may reduce omega-3 absorption)
  • ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)

Apport maximal tolérable : 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Ulcerative Colitis (UC)?
Based on 8 studies with 1,000 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Ulcerative Colitis (UC) management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Ulcerative Colitis (UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 8 peer-reviewed studies with 1,000 total participants. The overall direction of effect is mixed.

Omega-3 Fatty Acids (EPA/DHA) pour d'autres pathologies

References

  1. [1] Fares Jamal et al.. Dig Dis Sci. 2026. Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment. doi:10.1007/s10620-025-09387-z PubMed
  2. [2] Riya Gautam Naik et al.. Nutrients. 2025. From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel Disease Management. doi:10.3390/nu17030470 PubMed
  3. [3] D Fetarayani et al.. Semergen. 2025. Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit. doi:10.1016/j.semerg.2025.102575 PubMed
  4. [4] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
  5. [5] Kimsor Hong et al.. Autoimmun Rev. 2024. Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian randomization analysis. doi:10.1016/j.autrev.2024.103651 PubMed
  6. [6] Daniéla Oliveira Magro et al.. World J Gastroenterol. 2024. Interaction between diet and genetics in patients with inflammatory bowel disease. doi:10.3748/wjg.v30.i12.1644 PubMed
  7. [7] Xiaojing Jia et al.. Metabolites. 2023. Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study. doi:10.3390/metabo13101041 PubMed
  8. [8] Mina Movahedian et al.. Sci Rep. 2023. Association between dietary acid load and the odds of ulcerative colitis: a case-control study. doi:10.1038/s41598-023-41069-6 PubMed
  9. [9] Ammar Hassanzadeh Keshteli et al.. Nutrients. 2022. Anti-Inflammatory Diet Prevents Subclinical Colonic Inflammation and Alters Metabolomic Profile of Ulcerative Colitis Patients in Clinical Remission. doi:10.3390/nu14163294 PubMed
  10. [10] Marcelina Radziszewska et al.. Nutrients. 2022. Nutrition and Supplementation in Ulcerative Colitis. doi:10.3390/nu14122469 PubMed
  11. [11] Verônica Assalin Zorgetto-Pinheiro et al.. J Med Food. 2022. Omega-3 Fatty Acids and Balanced Gut Microbiota on Chronic Inflammatory Diseases: A Close Look at Ulcerative Colitis and Rheumatoid Arthritis … doi:10.1089/jmf.2021.0012 PubMed
  12. [12] Vishnu Kalladathvalappil Venugopalan et al.. Foods. 2021. Encapsulation and Protection of Omega-3-Rich Fish Oils Using Food-Grade Delivery Systems. doi:10.3390/foods10071566 PubMed
  13. [13] Jean-Frédéric LeBlanc et al.. Nutrients. 2021. The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis. doi:10.3390/nu13061780 PubMed
  14. [14] Robert Carreras-Torres et al.. Sci Rep. 2020. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. doi:10.1038/s41598-020-76361-2 PubMed
  15. [15] Sherman Picardo et al.. Therap Adv Gastroenterol. 2020. Complementary and alternative medications in the management of inflammatory bowel disease. doi:10.1177/1756284820927550 PubMed
  16. [16] Mohita Sharma et al.. Toxicol Mech Methods. 2019. Redox modulatory protective effects of ω-3 fatty acids rich fish oil against experimental colitis. doi:10.1080/15376516.2018.1553220 PubMed
  17. [17] Masako Nakanishi et al.. Nutrients. 2019. Dietary Walnut Supplementation Alters Mucosal Metabolite Profiles During DSS-Induced Colonic Ulceration. doi:10.3390/nu11051118 PubMed
  18. [18] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
  19. [19] Eleonora Scaioli et al.. Int J Mol Sci. 2017. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. doi:10.3390/ijms18122619 PubMed
  20. [20] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
  21. [21] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
  22. [22] Sandra Maria Barbalho et al.. Ann Gastroenterol. 2016. Inflammatory bowel disease: can omega-3 fatty acids really help? PubMed
  23. [23] Raquel Cristina Schwanke et al.. Eur J Pharmacol. 2016. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. doi:10.1016/j.ejphar.2015.08.050 PubMed
  24. [24] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
  25. [25] Meagen McCusker et al.. Clin Dermatol. 2016. Nutrition and skin: Kids are not just little people. doi:10.1016/j.clindermatol.2016.07.004 PubMed
  26. [26] Suneela S Dhaneshwar. World J Gastroenterol. 2014. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. doi:10.3748/wjg.v20.i13.3564 PubMed
  27. [27] Affifa Farrukh et al.. World J Clin Cases. 2014. Is there a role for fish oil in inflammatory bowel disease? doi:10.12998/wjcc.v2.i7.250 PubMed
  28. [28] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
  29. [29] Mi-Kyung Sung et al.. World J Gastroenterol. 2013. Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. doi:10.3748/wjg.v19.i7.994 PubMed
  30. [30] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
  31. [31] Fiona J Bath-Hextall et al.. Cochrane Database Syst Rev. 2012. Dietary supplements for established atopic eczema. doi:10.1002/14651858.CD005205.pub3 PubMed
  32. [32] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
  33. [33] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
  34. [34] Jason K Hou et al.. Am J Gastroenterol. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. doi:10.1038/ajg.2011.44 PubMed
  35. [35] Dan Turner et al.. Inflamm Bowel Dis. 2011. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. doi:10.1002/ibd.21374 PubMed
  36. [36] Gerard E Mullin. Nutr Clin Pract. 2011. Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses. doi:10.1177/0884533611400087 PubMed
  37. [37] Cinzia Papadia et al.. JRSM Short Rep. 2010. Omega-3 fatty acids in the maintenance of ulcerative colitis. doi:10.1258/shorts.2010.010004 PubMed
  38. [38] Hisayuki Matsunaga et al.. Inflamm Bowel Dis. 2008. Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. doi:10.1002/ibd.20491 PubMed
  39. [39] D Turner et al.. Cochrane Database Syst Rev. 2007. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. doi:10.1002/14651858.CD006443.pub2 PubMed
  40. [40] R Borneo et al.. J Food Sci. 2007. Stability and consumer acceptance of long-chain omega-3 fatty acids (eicosapentaenoic acid, 20:5, n-3 and docosahexaenoic acid, 22:6, n-3) in cream-filled … doi:10.1111/j.1750-3841.2006.00240.x PubMed
  41. [41] Décio Sabbatini Barbosa et al.. Nutrition. 2003. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. doi:10.1016/s0899-9007(03)00162-x PubMed
  42. [42] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
  43. [43] Artemis P Simopoulos. J Am Coll Nutr. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. doi:10.1080/07315724.2002.10719248 PubMed
  44. [44] I Dichi et al.. Nutrition. 2000. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. doi:10.1016/s0899-9007(99)00231-2 PubMed
  45. [45] A Heller et al.. Drugs. 1998. Lipid mediators in inflammatory disorders. doi:10.2165/00003495-199855040-00001 PubMed
  46. [46] Y Z Almallah et al.. Am J Gastroenterol. 1998. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. doi:10.1111/j.1572-0241.1998.229_a.x PubMed
  47. [47] A Burke et al.. Baillieres Clin Gastroenterol. 1997. Nutrition and ulcerative colitis. doi:10.1016/s0950-3528(97)90059-2 PubMed
  48. [48] M Bartels et al.. Langenbecks Arch Chir. 1995. [What is the role of nutrition in ulcerative colitis? A contribution to the current status of diet therapy in treatment … doi:10.1007/BF00184410 PubMed
  49. [49] A Aslan et al.. Am J Gastroenterol. 1992. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. PubMed
  50. [50] A P Simopoulos. Am J Clin Nutr. 1991. Omega-3 fatty acids in health and disease and in growth and development. doi:10.1093/ajcn/54.3.438 PubMed

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.